232 related articles for article (PubMed ID: 1347797)
1. Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp160.
Benjouad A; Gluckman JC; Rochat H; Montagnier L; Bahraoui E
J Virol; 1992 Apr; 66(4):2473-83. PubMed ID: 1347797
[TBL] [Abstract][Full Text] [Related]
2. Specificity of antibodies produced against native or desialylated human immunodeficiency virus type 1 recombinant gp160.
Benjouad A; Gluckman JC; Montagnier L; Bahraoui E
J Virol; 1993 Mar; 67(3):1693-7. PubMed ID: 7679751
[TBL] [Abstract][Full Text] [Related]
3. Effects of adjuvants and multiple antigen peptides on humoral and cellular immune responses to gp160 of HIV-1.
Levi M; Rudén U; Birx D; Loomis L; Redfield R; Lövgren K; Akerblom L; Sandström E; Wahren B
J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):855-64. PubMed ID: 8315572
[TBL] [Abstract][Full Text] [Related]
4. Effect of sialic acid removal on the antibody response to the third variable domain of human immunodeficiency virus type-1 envelope glycoprotein.
Benjouad A; Mabrouk K; Gluckman JC; Fenouillet E
FEBS Lett; 1994 Mar; 341(2-3):244-50. PubMed ID: 8137947
[TBL] [Abstract][Full Text] [Related]
5. Effect of a glucosidase inhibitor on the bioactivity and immunoreactivity of human immunodeficiency virus type 1 envelope glycoprotein.
Fenouillet E; Gluckman JC
J Gen Virol; 1991 Aug; 72 ( Pt 8)():1919-26. PubMed ID: 1678778
[TBL] [Abstract][Full Text] [Related]
6. Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response.
Bolmstedt A; Sjölander S; Hansen JE; Akerblom L; Hemming A; Hu SL; Morein B; Olofsson S
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul; 12(3):213-20. PubMed ID: 8673525
[TBL] [Abstract][Full Text] [Related]
7. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
Graham BS; Matthews TJ; Belshe RB; Clements ML; Dolin R; Wright PF; Gorse GJ; Schwartz DH; Keefer MC; Bolognesi DP
J Infect Dis; 1993 Mar; 167(3):533-7. PubMed ID: 8095059
[TBL] [Abstract][Full Text] [Related]
8. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.
Viscidi R; Ellerbeck E; Garrison L; Midthun K; Clements ML; Clayman B; Fernie B; Smith G
AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1251-6. PubMed ID: 1706607
[TBL] [Abstract][Full Text] [Related]
9. Induction of antibodies to the envelope protein of the human immunodeficiency virus by immunization with monoclonal anti-idiotypes.
Zaghouani H; Goldstein D; Shah H; Anderson S; Lacroix M; Dionne G; Kennedy R; Bona C
Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5645-9. PubMed ID: 2062842
[TBL] [Abstract][Full Text] [Related]
10. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
[TBL] [Abstract][Full Text] [Related]
11. Fine specificity of the murine antibody response to HIV-1 gp160 determined by synthetic peptides which define selected epitopes.
Wolf H; Warren RQ; Stunz GW; Shuler KR; Kanda P; Kennedy RC
Mol Immunol; 1992; 29(7-8):989-98. PubMed ID: 1378936
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD4 anti-idiotype antibodies in volunteers immunized with rgp160 of HIV-1 or infected with HIV-1.
Keay S; Tacket CO; Murphy JR; Handwerger BS
AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1091-8. PubMed ID: 1503823
[TBL] [Abstract][Full Text] [Related]
13. Specificity of antipeptide antibodies produced against V2 and V3 regions of the external envelope of human immunodeficiency virus type 2.
Babas T; Benichou S; Guetard D; Montagnier L; Bahraoui E
Mol Immunol; 1994 Apr; 31(5):361-9. PubMed ID: 8152439
[TBL] [Abstract][Full Text] [Related]
14. Detection of binding antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins following recombinant gp160 immunization measured by flow cytometry and enzyme immunoassays. The AIDS Vaccine Clinical Trials Network.
Gorse GJ; Frey SE; Newman FK; Belshe RB
J Clin Microbiol; 1992 Oct; 30(10):2606-12. PubMed ID: 1400960
[TBL] [Abstract][Full Text] [Related]
15. Production of long-lived neutralizing antibodies to HIV-1 IIIB in mice with a vaccinia recombinant virus-infected cell vaccine expressing gp160.
Parry C; McLain L; Dimmock NJ
AIDS Res Hum Retroviruses; 1994 Feb; 10(2):205-12. PubMed ID: 8198873
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers.
Salmon-Céron D; Excler JL; Sicard D; Blanche P; Finkielstzjen L; Gluckman JC; Autran B; Matthews TJ; Meignier B; Kieny MP
AIDS Res Hum Retroviruses; 1995 Dec; 11(12):1479-86. PubMed ID: 8679292
[TBL] [Abstract][Full Text] [Related]
17. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.
Pincus SH; Messer KG; Schwartz DH; Lewis GK; Graham BS; Blattner WA; Fisher G
J Clin Invest; 1993 May; 91(5):1987-96. PubMed ID: 7683694
[TBL] [Abstract][Full Text] [Related]
18. Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. NIAID AIDS Vaccine Clinical Trials Network.
Gorse GJ; Frey SE; Patel G; Newman FK; Belshe RB
Vaccine; 1994 Aug; 12(10):912-8. PubMed ID: 7975833
[TBL] [Abstract][Full Text] [Related]
19. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160.
Mosier DE; Gulizia RJ; MacIsaac PD; Corey L; Greenberg PD
Proc Natl Acad Sci U S A; 1993 Mar; 90(6):2443-7. PubMed ID: 8460155
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of synthetic peptides corresponding to various epitopes of the human immunodeficiency virus envelope protein.
Zaghouani H; Hall B; Shah H; Bona C
Adv Exp Med Biol; 1991; 303():53-62. PubMed ID: 1725238
[No Abstract] [Full Text] [Related]
[Next] [New Search]
